Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1647 CMV Vaccine in Healthy Adults
NCT04232280Phase 2Completed
- Sponsor
- Moderna Inc
- Start
- Jan 2020
- Primary completion
- Jan 2023
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of mRNA-1647 in cytomegalovirus infection (CMV), sponsored by Moderna Inc. Started Jan 2020; status: completed.
02
Drugs
mRNA-1647
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT04232280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04232280.